Published DateClear

Start Date

End Date

Category

• Business2
• Pipeline1

Organizations

• Bausch + Lomb72
• Eyes On Eyecare55
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Coopervision19

Tags

• AMD3
• DME2
• Acquisitions2
• Clinical Trials2
• Retina2
• Wet Amd2
• Injections1

• Organizations: Merck✕

Clear all

Pipeline

Merck kicks off phase 2b/3 trial on tri-specific antibody for wet AMD

Merck initiates next phase of clinical testing in ophthalmology with two candidates targeting nAMD and DME.

Business

Merck officially enters ophthalmic space with EyeBio acquisition

Pharmaceutical giant now owns Restoret (EYE103), an investigational, tri-specific antibody for DME and wet AMD.

Business

Merck to acquire Eyebiotech in deal worth up to $3B

Agreement involves EyeBio’s lead retinal vascular disease candidate, Restoret, designed as an intravitreal injection for DME and wet AMD patients.